Brand names: Mycapssa
Somatostatin Analog · Somatostatin Receptor Agonists
3 interactions on record
Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed ( 7 ). Lisinopril Clinical Impact: Concomitant administration of MYCAPSSA increases lisinopril bioavailability [see Clinical Pharmacology (12.3) ] . Intervention: Monitor patient's blood pressure and adjust the dosage of lisinopril if needed.
Source: FDA drug label - octreotide
7.1 Effects of Other Drugs on MYCAPSSA Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids Clinical Impact: Concomitant administration of MYCAPSSA with esomeprazole resulted in a decrease in the bioavailability for MYCAPSSA [ See Clinical Pharmacology (12.3) ] .
Source: FDA drug label - octreotide
Drugs Metabolized by CYP 450 Enzymes Clinical Impact: Limited published data indicate that somatostatin analogs including MYCAPSSA may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH.
Source: FDA drug label - octreotide